ReviewFrontiers in oncology2023

SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process.

Moqin Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.